



# SMOFlipid® 20 %

## Unique 4-oil lipid emulsion

Intravenous lipid emulsion for use as part of parenteral nutrition as a source of energy and essential fatty acids.

100 g lipids per 500 mL

30 % Soybean oil for essential fatty acids

30 % Medium chain triglycerides for rapidly available energy

25 % Olive oil for monounsaturated fatty acids

15 % Fish oil - Provides omega-3 fatty acids, especially EPA\* and DHA\*\*

Additional Vitamin E (approx. 200 mg α-tocopherol/litre) To help counteract lipid peroxidation and oxidative stress<sup>1</sup>

For Healthcare Professionals only.

\* EPA = eicosapentaenoic acid  
\*\* DHA = docosahexaenoic acid


# SMOFlipid® 20 %



SMOFlipid has shown numerous benefits when included as part of parenteral nutrition (PN)



- Positive effects on liver cell function<sup>2</sup> and integrity<sup>3</sup>



- Controlled serum triglycerides<sup>3</sup>



- Favourable immune and inflammatory response<sup>4</sup>



- Improved antioxidant status<sup>5</sup>

## Benefits of Omega-3 Containing Parenteral Nutrition

**A meta-analysis\* in adult ICU patients showed that parenteral nutrition containing omega-3 fatty acids had beneficial effects and lead to less complications as well as faster hospital discharge<sup>6</sup>.**

\*Meta-analysis of 24 randomised controlled trials including n=1421 patients comparing omega-3 fatty acid enriched lipid emulsions with standard lipid emulsions in ICU patients receiving parenteral nutrition.



### Shorter length of ICU stay

Significant reduction of ICU length of stay by 1,89 days



### Shorter length of hospital stay

Significant reduction in hospital stay by 3 days



### Lower infection rate

38 % significant reduction in relative risk of infection rate in ICU patients



### Cost saving

Overall hospital costs reduced between €3 156 and €9 586

## Consensus Statements from Expert Panel Participating in International Lipids in PN Summit (2022):<sup>7</sup>

**Statement 7:** The use of **intravenous lipid emulsions (ILEs) containing fish oil should be considered during the first week** of ICU admission in adult **patients requiring PN including surgical and critically ill patients**, based on biological plausibility and associated clinical benefits.

**Statement 8:** There is accumulating scientific evidence from clinical trials, systematic reviews, and meta-analyses to demonstrate that **ILEs containing fish oil have clinically meaningful advantages** over ILEs without fish oil when used in adult patients requiring PN including surgical and critically ill patients with a **favourable risk-benefit ratio**. Furthermore, the use of ILEs containing fish oil as part of PN has **shown to be cost-effective** in these populations.

**Statement 10:** Based on currently available clinical data, we recommend **0,1-0,2 g fish oil/kg/day**, provided by lipid emulsions containing fish oil, for adult medical and surgical ICU patients requiring PN.

1. Biesalski HK. Gastroenterology. 2009 Nov;137(5 Suppl):S92-104. doi: 10.1053/j.gastro.2009.07.073. PMID: 19874955. 2. Klek S, Chambrier C, Singer P, et al. Clin Nutr. 2013 Apr;32(2):224-31. doi: 10.1016/j.clnu.2012.06.011. 3. Piper SN, Schade I, Beschmann RB, et al. Eur J Anaesthesiol. 2009 Dec;26(12):1076-82. doi: 10.1097/eja.0b013e32832e08e0. PMID: 19916246. 4. Schade I, Röhm KD, Schellhaass A, et al. Crit Care 2008;12(2):S56-S57. Abstract P144 (detailed information regarding the study design and further results in Piper SN et al. Eur J Anaesthesiol 2009;26(12):1076-1082). 5. Antébi H, Mansoor O, Ferrier C, et al. JPEN J Parenter Enteral Nutr. 2004 May-Jun;28(3):142-8. doi: 10.1177/0148607104028003142. PMID: 15141405. 6. Pradelli L, Klek S, Mayer K, et al. Crit Care. 2020 Nov 3;24(1):634. doi: 10.1186/s13054-020-03356-w. PMID: 33143750; PMCID: PMC7607851. 7. Stoppe C, Martindale RG, Klek S, Calder PC, et al. Crit Care. 2024 Aug 12;28(1):271. doi: 10.1186/s13054-024-05053-4. PMID: 39135117; PMCID: PMC11321210.



**FRESENIUS  
KABI**

Fresenius Kabi South Africa (Pty) Ltd,  
Reg. No.: 1998/006230/07  
Stand 7, Growthpoint Business Park  
162 Tonetti Street, Halfway House  
Extension 7, Midrand, Gauteng, 1685  
PO Box 4156, Halfway House 1685  
Tel: + 27 11 545 0000 Fax: + 27 11 545 0060  
www.fresenius-kabi.co.za

**S3** SMOFlipid® 20 %. Reg. No.: 41/25.2/0060  
Each 1 000 ml emulsion contains 60,0 g soybean oil; 50,0 g olive oil; 30,0 g fish oil; 60,0 g medium chain triglycerides.  
For full prescribing information please refer to the latest professional information approved by the South African Health Products Regulatory Authority.